9MQI image
Deposition Date 2025-01-03
Release Date 2025-02-12
Last Version Date 2025-02-12
Entry Detail
PDB ID:
9MQI
Title:
Inactive Mu-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound #020_E1
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.30 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Mu-type opioid receptor
Gene (Uniprot):OPRM1
Chain IDs:A
Chain Length:411
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Nanobody 6M
Chain IDs:B (auth: C)
Chain Length:131
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polypeptide(L)
Molecule:NabFab Heavy Chain
Chain IDs:C (auth: H)
Chain Length:239
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polypeptide(L)
Molecule:NabFab Light Chain
Chain IDs:D (auth: L)
Chain Length:215
Number of Molecules:1
Biological Source:synthetic construct
Ligand Molecules
Primary Citation
Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Biorxiv ? ? ? (2025)
PMID: 39868130 DOI: 10.1101/2025.01.09.632033

Abstact

Large library docking of tangible molecules has revealed potent ligands across many targets. While make-on-demand libraries now exceed 75 billion enumerated molecules, their synthetic routes are dominated by a few reaction types, reducing diversity and inevitably leaving many interesting bioactive-like chemotypes unexplored. Here, we investigate the large-scale enumeration and targeted docking of isoquinuclidines. These "natural-product-like" molecules are rare in the current libraries and are functionally congested, making them interesting as receptor probes. Using a modular, four-component reaction scheme, we built and docked a virtual library of over 14.6 million isoquinuclidines against both the μ- and κ-opioid receptors (MOR and KOR, respectively). Synthesis and experimental testing of 18 prioritized compounds found nine ligands with low μM affinities. Structure-based optimization revealed low- and sub-nM antagonists and inverse agonists targeting both receptors. Cryo-electron microscopy (cryoEM) structures illuminate the origins of activity on each target. In mouse behavioral studies, a potent member of the series with joint MOR-antagonist and KOR-inverse-agonist activity reversed morphine-induced analgesia, phenocopying the MOR-selective anti-overdose agent naloxone. Encouragingly, the new molecule induced less severe opioid-induced withdrawal symptoms compared to naloxone during withdrawal precipitation, and did not induce conditioned-place aversion, likely reflecting a reduction of dysphoria due to the compound's KOR-inverse agonism. The strengths and weaknesses of bespoke library docking, and of docking for opioid receptor polypharmacology, will be considered.

Legend

Protein

Chemical

Disease

Primary Citation of related structures